Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FRA:2LS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.87 Med: 13.46 Max: 73.71
Current: 10.79
During the past 13 years, the highest EV-to-EBITDA of PT Siloam International Hospitals Tbk was 73.71. The lowest was 5.87. And the median was 13.46.
FRA:2LS's EV-to-EBITDA is ranked better than 51.08% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.89
vs FRA:2LS: 10.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
PT Siloam International Hospitals Tbk (FRA:2LS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Siloam International Hospitals Tbk's PE Ratio (TTM) for today is calculated as:
PT Siloam International Hospitals Tbk's share price for today is €0.099.
PT Siloam International Hospitals Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Siloam International Hospitals Tbk EV-to-EBITDA Chart
For the Medical Care Facilities subindustry, PT Siloam International Hospitals Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Siloam International Hospitals Tbk EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Siloam International Hospitals Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Siloam International Hospitals Tbk's EV-to-EBITDA falls into.
PT Siloam International Hospitals Tbk's current Enterprise Value is €1,449.8 Mil.
PT Siloam International Hospitals Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €142.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Siloam International Hospitals Tbk (FRA:2LS) has a EV-to-EBITDA of 10.18 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Siloam International Hospitals Tbk. This is 24% below median its historical median of 13.46. Over the past decade, PT Siloam International Hospitals Tbk's EV-to-EBITDA has ranged from 5.87 to 73.71. According to the industry distribution chart, PT Siloam International Hospitals Tbk ranks #248 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 48.9%.
Is PT Siloam International Hospitals Tbk's EV-to-EBITDA too high?
PT Siloam International Hospitals Tbk's current EV-to-EBITDA of 10.18 is 24% below median its 10-year median of 13.46. Over the past 10 years, this metric has ranged from a low of 5.87 to a high of 73.71. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.89. PT Siloam International Hospitals Tbk's value of 10.18 is 6.5% below this industry median. Based on the distribution chart, PT Siloam International Hospitals Tbk ranks #248 out of 507 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, PT Siloam International Hospitals Tbk has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does PT Siloam International Hospitals Tbk's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Siloam International Hospitals Tbk ranks #248 out of 507 companies for EV-to-EBITDA. This puts PT Siloam International Hospitals Tbk in the upper half of its industry. The industry median EV-to-EBITDA is 10.89. PT Siloam International Hospitals Tbk's value of 10.18 is 6.5% below this benchmark. Historically, PT Siloam International Hospitals Tbk's own EV-to-EBITDA has ranged from 5.87 to 73.71 over the past decade. While the company's 10-year median is 13.46 vs. the industry median of 10.89, PT Siloam International Hospitals Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.89, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Siloam International Hospitals Tbk's current EV-to-EBITDA of 10.18 is 6.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Siloam International Hospitals Tbk. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Siloam International Hospitals Tbk's current EV-to-EBITDA is 10.18, which is 24% below median its own 10-year median of 13.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Siloam International Hospitals Tbk stock overvalued right now?
PT Siloam International Hospitals Tbk (FRA:2LS) has a current EV-to-EBITDA of 10.18. The stock's GF Value™ is €0.12, compared to a current price of €0.10 — trading 17.5% below its estimated fair value. The current EV-to-EBITDA is 10.18, which is 24% below median its 10-year median of 13.46 and 6.5% below the Healthcare Providers & Services industry median of 10.89. PT Siloam International Hospitals Tbk's overall GF Score™ is 94/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Siloam International Hospitals Tbk (FRA:2LS), the current EV-to-EBITDA is 10.18 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Siloam International Hospitals Tbk (FRA:2LS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Siloam International Hospitals Tbk stock appears to be undervalued.
The current stock price of €0.10 is trading 17.5% below its estimated GF Value™ of €0.12.
Key valuation signals for FRA:2LS:
EV-to-EBITDA: 10.18 (24% below median its 10-year median of 13.46)
GF Value™: €0.12 vs. price of €0.10 (17.5% below fair value)
Industry Position: 6.5% below the Healthcare Providers & Services median (#248 of 507)
No single metric tells the full story. See the FRA:2LS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Siloam International Hospitals Tbk Business Description
PT Siloam International Hospitals Tbk operates a network of hospitals in Indonesia. Its hospitals are located in the Greater Jakarta area and across Java, Sumatra, Kalimantan, Sulawesi, Bali, Nusa Tenggara, Ambon, and other areas across Indonesia, along with several Siloam Clinics. The company offers an integrated, one-stop care ecosystem designed to provide comprehensive healthcare services, spanning examination, diagnosis, clinical management, rehabilitation, and health education. Additionally, it offers special clinical services in the following segments, including neurosciences, neurology, digestive, cardiac, orthopedic, etc., by running the Center of Excellence and specialty centers. The company generates the majority of its revenue by offering hospitalization and outpatient services.
94GF Score
Get the complete analysis for FRA:2LS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2LS has been successfully added to your 
